2018-2023 Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Report

October 2018 | 135 pages | ID: 2FEA2281414EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Postmenopausal Vaginal Atrophy Drugs market for 2018-2023.

Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
Over the next five years, LPI(LP Information) projects that Postmenopausal Vaginal Atrophy Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Postmenopausal Vaginal Atrophy Drugs market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

• Premarin
• Vagifem
• Estrace
• Estring
• Femring

Segmentation by application:

• Vaginal Gels
• Creams
• Tablets
• Rings
• Patches

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

• Actavis plc
• Bionovo, Inc.
• Endoceutics, Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Teva Pharmaceuticals Ltd.
• Therapeutics MD, Inc.
• Shionogi & Company
• Allergan plc
• Shionogi & Co. Ltd.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Postmenopausal Vaginal Atrophy Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Postmenopausal Vaginal Atrophy Drugs market by identifying its various subsegments.
• Focuses on the key global Postmenopausal Vaginal Atrophy Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Postmenopausal Vaginal Atrophy Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Postmenopausal Vaginal Atrophy Drugs submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption 2013-2023
  2.1.2 Postmenopausal Vaginal Atrophy Drugs Consumption CAGR by Region
2.2 Postmenopausal Vaginal Atrophy Drugs Segment by Type
  2.2.1 Premarin
  2.2.2 Vagifem
  2.2.3 Estrace
  2.2.4 Estring
  2.2.5 Femring
2.3 Postmenopausal Vaginal Atrophy Drugs Consumption by Type
  2.3.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type (2013-2018)
  2.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Type (2013-2018)
  2.3.3 Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Type (2013-2018)
2.4 Postmenopausal Vaginal Atrophy Drugs Segment by Application
  2.4.1 Vaginal Gels
  2.4.2 Creams
  2.4.3 Tablets
  2.4.4 Rings
  2.4.5 Patches
2.5 Postmenopausal Vaginal Atrophy Drugs Consumption by Application
  2.5.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application (2013-2018)
  2.5.2 Global Postmenopausal Vaginal Atrophy Drugs Value and Market Share by Application (2013-2018)
  2.5.3 Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Application (2013-2018)

3 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS BY PLAYERS

3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Players
  3.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Players (2016-2018)
  3.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Players (2016-2018)
3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Players
  3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Players (2016-2018)
  3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Players (2016-2018)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Players
3.4 Global Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
  3.4.1 Global Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution and Sales Area by Players
  3.4.2 Players Postmenopausal Vaginal Atrophy Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 POSTMENOPAUSAL VAGINAL ATROPHY DRUGS BY REGIONS

4.1 Postmenopausal Vaginal Atrophy Drugs by Regions
  4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption by Regions
  4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Value by Regions
4.2 Americas Postmenopausal Vaginal Atrophy Drugs Consumption Growth
4.3 APAC Postmenopausal Vaginal Atrophy Drugs Consumption Growth
4.4 Europe Postmenopausal Vaginal Atrophy Drugs Consumption Growth
4.5 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Growth

5 AMERICAS

5.1 Americas Postmenopausal Vaginal Atrophy Drugs Consumption by Countries
  5.1.1 Americas Postmenopausal Vaginal Atrophy Drugs Consumption by Countries (2013-2018)
  5.1.2 Americas Postmenopausal Vaginal Atrophy Drugs Value by Countries (2013-2018)
5.2 Americas Postmenopausal Vaginal Atrophy Drugs Consumption by Type
5.3 Americas Postmenopausal Vaginal Atrophy Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Postmenopausal Vaginal Atrophy Drugs Consumption by Countries
  6.1.1 APAC Postmenopausal Vaginal Atrophy Drugs Consumption by Countries (2013-2018)
  6.1.2 APAC Postmenopausal Vaginal Atrophy Drugs Value by Countries (2013-2018)
6.2 APAC Postmenopausal Vaginal Atrophy Drugs Consumption by Type
6.3 APAC Postmenopausal Vaginal Atrophy Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Countries
  7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Consumption by Countries (2013-2018)
  7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Value by Countries (2013-2018)
7.2 Europe Postmenopausal Vaginal Atrophy Drugs Consumption by Type
7.3 Europe Postmenopausal Vaginal Atrophy Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs by Countries
  8.1.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption by Countries (2013-2018)
  8.1.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Value by Countries (2013-2018)
8.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption by Type
8.3 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
10.2 Postmenopausal Vaginal Atrophy Drugs Distributors
10.3 Postmenopausal Vaginal Atrophy Drugs Customer

11 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FORECAST

11.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2018-2023)
11.2 Global Postmenopausal Vaginal Atrophy Drugs Forecast by Regions
  11.2.1 Global Postmenopausal Vaginal Atrophy Drugs Forecast by Regions (2018-2023)
  11.2.2 Global Postmenopausal Vaginal Atrophy Drugs Value Forecast by Regions (2018-2023)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
  11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Postmenopausal Vaginal Atrophy Drugs Forecast by Type
11.8 Global Postmenopausal Vaginal Atrophy Drugs Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 Actavis plc
  12.1.1 Company Details
  12.1.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.1.4 Main Business Overview
  12.1.5 Actavis plc News
12.2 Bionovo, Inc.
  12.2.1 Company Details
  12.2.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.2.4 Main Business Overview
  12.2.5 Bionovo, Inc. News
12.3 Endoceutics, Inc.
  12.3.1 Company Details
  12.3.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.3.4 Main Business Overview
  12.3.5 Endoceutics, Inc. News
12.4 Novo Nordisk A/S
  12.4.1 Company Details
  12.4.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.4.4 Main Business Overview
  12.4.5 Novo Nordisk A/S News
12.5 Pfizer Inc.
  12.5.1 Company Details
  12.5.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.5.4 Main Business Overview
  12.5.5 Pfizer Inc. News
12.6 Teva Pharmaceuticals Ltd.
  12.6.1 Company Details
  12.6.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.6.4 Main Business Overview
  12.6.5 Teva Pharmaceuticals Ltd. News
12.7 Therapeutics MD, Inc.
  12.7.1 Company Details
  12.7.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.7.4 Main Business Overview
  12.7.5 Therapeutics MD, Inc. News
12.8 Shionogi & Company
  12.8.1 Company Details
  12.8.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.8.4 Main Business Overview
  12.8.5 Shionogi & Company News
12.9 Allergan plc
  12.9.1 Company Details
  12.9.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.9.4 Main Business Overview
  12.9.5 Allergan plc News
12.10 Shionogi & Co. Ltd.
  12.10.1 Company Details
  12.10.2 Postmenopausal Vaginal Atrophy Drugs Product Offered
  12.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.10.4 Main Business Overview
  12.10.5 Shionogi & Co. Ltd. News

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Postmenopausal Vaginal Atrophy Drugs
Table Product Specifications of Postmenopausal Vaginal Atrophy Drugs
Figure Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure Market Research Methodology
Figure Global Postmenopausal Vaginal Atrophy Drugs Consumption Growth Rate 2013-2023 (K Units)
Figure Global Postmenopausal Vaginal Atrophy Drugs Value Growth Rate 2013-2023 ($ Millions)
Table Postmenopausal Vaginal Atrophy Drugs Consumption CAGR by Region 2013-2023 ($ Millions)
Figure Product Picture of Premarin
Table Major Players of Premarin
Figure Product Picture of Vagifem
Table Major Players of Vagifem
Figure Product Picture of Estrace
Table Major Players of Estrace
Figure Product Picture of Estring
Table Major Players of Estring
Figure Product Picture of Femring
Table Major Players of Femring
Table Global Consumption Sales by Type (2013-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type (2013-2018)
Figure Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type (2013-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2013-2018) ($ million)
Table Global Postmenopausal Vaginal Atrophy Drugs Value Market Share by Type (2013-2018) ($ Millions)
Figure Global Postmenopausal Vaginal Atrophy Drugs Value Market Share by Type (2013-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Type (2013-2018)
Figure Postmenopausal Vaginal Atrophy Drugs Consumed in Vaginal Gels
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Vaginal Gels (2013-2018) (K Units)
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Vaginal Gels (2013-2018) ($ Millions)
Figure Global Vaginal Gels YoY Growth ($ Millions)
Figure Postmenopausal Vaginal Atrophy Drugs Consumed in Creams
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Creams (2013-2018) (K Units)
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Creams (2013-2018) ($ Millions)
Figure Global Creams YoY Growth ($ Millions)
Figure Postmenopausal Vaginal Atrophy Drugs Consumed in Tablets
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Tablets (2013-2018) (K Units)
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Tablets (2013-2018) ($ Millions)
Figure Global Tablets YoY Growth ($ Millions)
Figure Postmenopausal Vaginal Atrophy Drugs Consumed in Rings
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Rings (2013-2018) (K Units)
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Rings (2013-2018) ($ Millions)
Figure Global Rings YoY Growth ($ Millions)
Figure Postmenopausal Vaginal Atrophy Drugs Consumed in Patches
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Patches (2013-2018) (K Units)
Figure Global Postmenopausal Vaginal Atrophy Drugs Market: Patches (2013-2018) ($ Millions)
Figure Global Patches YoY Growth ($ Millions)
Table Global Consumption Sales by Application (2013-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application (2013-2018)
Figure Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application (2013-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Value by Application (2013-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Value Market Share by Application (2013-2018)
Figure Global Postmenopausal Vaginal Atrophy Drugs Value Market Share by Application (2013-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Application (2013-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Sales by Players (2016-2018) (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Players (2016-2018)
Figure Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Players in 2016
Figure Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Players in 2017
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue by Players (2016-2018) ($ Millions)
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Players (2016-2018)
Figure Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Players in 2016
Figure Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Players in 2017
Table Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Players (2016-2018)
Figure Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Players in 2017
Table Global Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution and Sales Area by Players
Table Players Postmenopausal Vaginal Atrophy Drugs Products Offered
Table Postmenopausal Vaginal Atrophy Drugs Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption by Regions 2013-2018 (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Regions 2013-2018
Figure Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Regions 2013-2018
Table Global Postmenopausal Vaginal Atrophy Drugs Value by Regions 2013-2018 ($ Millions)
Table Global Postmenopausal Vaginal Atrophy Drugs Value Market Share by Regions 2013-2018
Figure Global Postmenopausal Vaginal Atrophy Drugs Value Market Share by Regions 2013-2018
Figure Americas Postmenopausal Vaginal Atrophy Drugs Consumption 2013-2018 (K Units)
Figure Americas Postmenopausal Vaginal Atrophy Drugs Value 2013-2018 ($ Millions)
Figure APAC Postmenopausal Vaginal Atrophy Drugs Consumption 2013-2018 (K Units)
Figure APAC Postmenopausal Vaginal Atrophy Drugs Value 2013-2018 ($ Millions)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Consumption 2013-2018 (K Units)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Value 2013-2018 ($ Millions)
Figure Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption 2013-2018 (K Units)
Figure Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Value 2013-2018 ($ Millions)
Table Americas Postmenopausal Vaginal Atrophy Drugs Consumption by Countries (2013-2018) (K Units)
Table Americas Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Countries (2013-2018)
Figure Americas Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Countries in 2017
Table Americas Postmenopausal Vaginal Atrophy Drugs Value by Countries (2013-2018) ($ Millions)
Table Americas Postmenopausal Vaginal Atrophy Drugs Value Market Share by Countries (2013-2018)
Figure Americas Postmenopausal Vaginal Atrophy Drugs Value Market Share by Countries in 2017
Table Americas Postmenopausal Vaginal Atrophy Drugs Consumption by Type (2013-2018) (K Units)
Table Americas Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type (2013-2018)
Figure Americas Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type in 2017
Table Americas Postmenopausal Vaginal Atrophy Drugs Consumption by Application (2013-2018) (K Units)
Table Americas Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application (2013-2018)
Figure Americas Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application in 2017
Figure United States Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure United States Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Table APAC Postmenopausal Vaginal Atrophy Drugs Consumption by Countries (2013-2018) (K Units)
Table APAC Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Countries (2013-2018)
Figure APAC Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Countries in 2017
Table APAC Postmenopausal Vaginal Atrophy Drugs Value by Countries (2013-2018) ($ Millions)
Table APAC Postmenopausal Vaginal Atrophy Drugs Value Market Share by Countries (2013-2018)
Figure APAC Postmenopausal Vaginal Atrophy Drugs Value Market Share by Countries in 2017
Table APAC Postmenopausal Vaginal Atrophy Drugs Consumption by Type (2013-2018) (K Units)
Table APAC Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type (2013-2018)
Figure APAC Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type in 2017
Table APAC Postmenopausal Vaginal Atrophy Drugs Consumption by Application (2013-2018) (K Units)
Table APAC Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application (2013-2018)
Figure APAC Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application in 2017
Figure China Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure China Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Southeast Asia Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Southeast Asia Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure India Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure India Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Australia Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Australia Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Table Europe Postmenopausal Vaginal Atrophy Drugs Consumption by Countries (2013-2018) (K Units)
Table Europe Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Countries (2013-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Countries in 2017
Table Europe Postmenopausal Vaginal Atrophy Drugs Value by Countries (2013-2018) ($ Millions)
Table Europe Postmenopausal Vaginal Atrophy Drugs Value Market Share by Countries (2013-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Value Market Share by Countries in 2017
Table Europe Postmenopausal Vaginal Atrophy Drugs Consumption by Type (2013-2018) (K Units)
Table Europe Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type (2013-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type in 2017
Table Europe Postmenopausal Vaginal Atrophy Drugs Consumption by Application (2013-2018) (K Units)
Table Europe Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application (2013-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application in 2017
Figure Germany Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Germany Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure France Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure France Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure UK Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure UK Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Spain Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Spain Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Table Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption by Countries (2013-2018) (K Units)
Table Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Countries (2013-2018)
Figure Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Countries in 2017
Table Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Value by Countries (2013-2018) ($ Millions)
Table Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Value Market Share by Countries (2013-2018)
Figure Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Value Market Share by Countries in 2017
Table Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption by Type (2013-2018) (K Units)
Table Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type (2013-2018)
Figure Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Type in 2017
Table Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption by Application (2013-2018) (K Units)
Table Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application (2013-2018)
Figure Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application in 2017
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Israel Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Israel Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Figure GCC Countries Postmenopausal Vaginal Atrophy Drugs Consumption Growth 2013-2018 (K Units)
Figure GCC Countries Postmenopausal Vaginal Atrophy Drugs Value Growth 2013-2018 ($ Millions)
Table Postmenopausal Vaginal Atrophy Drugs Distributors List
Table Postmenopausal Vaginal Atrophy Drugs Customer List
Figure Global Postmenopausal Vaginal Atrophy Drugs Consumption Growth Rate Forecast (2018-2023) (K Units)
Figure Global Postmenopausal Vaginal Atrophy Drugs Value Growth Rate Forecast (2018-2023) ($ Millions)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Countries (2018-2023) (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Forecast by Regions
Table Global Postmenopausal Vaginal Atrophy Drugs Value Forecast by Countries (2018-2023) ($ Millions)
Table Global Postmenopausal Vaginal Atrophy Drugs Value Market Share Forecast by Regions
Figure Americas Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Americas Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure APAC Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure APAC Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure United States Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure United States Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure China Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure China Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Southeast Asia Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Southeast Asia Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure India Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure India Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Australia Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Australia Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Germany Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Germany Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure France Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure France Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure UK Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure UK Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Spain Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Spain Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Israel Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Israel Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Figure GCC Countries Postmenopausal Vaginal Atrophy Drugs Consumption 2018-2023 (K Units)
Figure GCC Countries Postmenopausal Vaginal Atrophy Drugs Value 2018-2023 ($ Millions)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Type (2018-2023) (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share Forecast by Type (2018-2023)
Table Global Postmenopausal Vaginal Atrophy Drugs Value Forecast by Type (2018-2023) ($ Millions)
Table Global Postmenopausal Vaginal Atrophy Drugs Value Market Share Forecast by Type (2018-2023)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Application (2018-2023) (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share Forecast by Application (2018-2023)
Table Global Postmenopausal Vaginal Atrophy Drugs Value Forecast by Application (2018-2023) ($ Millions)
Table Global Postmenopausal Vaginal Atrophy Drugs Value Market Share Forecast by Application (2018-2023)
Table Actavis plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Actavis plc Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Bionovo, Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Endoceutics, Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Novo Nordisk A/S Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Pfizer Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Teva Pharmaceuticals Ltd. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Therapeutics MD, Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Shionogi & Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Allergan plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Allergan plc Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)
Table Shionogi & Co. Ltd. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Market Share (2016-2018)